- Financial Performance
- 1 min read
Drugmaker Athenex voluntarily files for US Chapter 11 proceedings
Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets. The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy.
Read by
Athenex reached an agreement with its lenders to move forward with an expedited sale process of its assets, the company said in a statement.
The Buffalo, New York-based company has listed estimated assets and liabilities in the range of $100 million-$500 million, according to a filing with the US Bankruptcy Court for the Southern District of Texas.
The assets to be sold would be across its primary businesses of Athenex Pharmaceutical Division (APD), Orascovery, and Cell Therapy, the company said, adding that it expects the expedited process to be completed by July 1, 2023.
The company said it has sufficient resources to support Athenex Pharma Solutions operations, and fulfill APD customer orders during the sale process.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions